INSPIRE SIGNED
INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0INSPIRE project word cloud
Explore the words cloud of the INSPIRE project. It provides you a very rough idea of what is the project "INSPIRE" about.
Project "INSPIRE" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITEIT ANTWERPEN
Organization address contact info |
| Coordinator Country | Belgium [BE] |
| Total cost | 4˙021˙968 € |
| EC max contribution | 4˙021˙968 € (100%) |
| Programme |
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers) |
| Code Call | H2020-MSCA-ITN-2019 |
| Funding Scheme | MSCA-ITN-ETN |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-01-01 to 2023-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSITEIT ANTWERPEN | BE (ANTWERPEN) | coordinator | 768˙960.00 |
| 2 | THE UNIVERSITY OF NOTTINGHAM | UK (NOTTINGHAM) | participant | 606˙345.00 |
| 3 | NOTOCORD SYSTEMS | FR (LE PECQ) | participant | 549˙604.00 |
| 4 | UNIVERSITEIT MAASTRICHT | NL (MAASTRICHT) | participant | 531˙239.00 |
| 5 | INSTITUT NATIONAL DE RECHERCHE ENINFORMATIQUE ET AUTOMATIQUE | FR (LE CHESNAY CEDEX) | participant | 274˙802.00 |
| 6 | NCARDIA BV | NL (LEIDEN) | participant | 265˙619.00 |
| 7 | WEIZMANN INSTITUTE OF SCIENCE | IL (REHOVOT) | participant | 263˙500.00 |
| 8 | UCB BIOPHARMA SRL | BE (BRUXELLES) | participant | 256˙320.00 |
| 9 | BOEHRINGER INGELHEIM PHARMA GMBH &CO KG | DE (INGELHEIM) | participant | 252˙788.00 |
| 10 | TSE SYSTEMS GMBH | DE (BAD HOMBURG VOR DER HOHE) | participant | 252˙788.00 |
Map
Project objective
New drug candidates often have off-target effects resulting in adverse events, thus representing a major limitation for drug R&D. Safety Pharmacology (SP) aims to detect, understand and reduce undesirable pharmacodynamic effects early-on. Especially, cardiovascular (CV) toxicity is problematic, as it is the most prevalent reason for failure during preclinical development. Moreover, CV toxicity remains a key reason for drug attrition during clinical development and beyond. This indicates current SP screens fail to detect a number of (late-onset) functional or structural CV toxicities. Additionally, SP uses a significant number of laboratory animals, thereby creating opportunities for a better implementation of the 3Rs. The vision of INSPIRE is to advance and “inspire” SP by exploring new technological capabilities (WP1), addressing emerging CV concerns (WP2) and delivering new validated solutions for CV safety screening (WP3). To this end, INSPIRE unites expertise from academic teams, technology-providers, pharmaceutical companies, regulators and hospitals to create a European training platform for 15 Early Stage Researchers (ESRs). Key innovative aspects of INSPIRE include: i) in vitro humanized cardiomyocytes assays, ii) unparalleled in vivo hardware/software solutions, iii) in silico predictions of haemodynamics, iv) mass spectroscopy imaging of drug exposure, v) exploration of mechanisms of late-onset CV toxicity, as observed in cardio-oncology, and vi) early integration of feedback from industry and regulators. Overall, INSPIRE constitutes a multidisciplinary and intersectoral training programme (WP4) with a balanced combination of hands-on research training, intersectoral secondments, local courses and network-wide events on scientific and transferable skills, enabling future R&I collaborations. Hence, INSPIRE will equip the future generation of SP scientists with a wide range of scientific knowledge and the ability to adapt to a dynamic ever-changing industry.
Deliverables
| Start recruitment procedure | Other | 2020-02-27 15:24:01 |
Take a look to the deliverables list in detail: detailed list of INSPIRE deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INSPIRE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "INSPIRE" are provided by the European Opendata Portal: CORDIS opendata.